SCHEMBL5495502

SCHEMBL5495502

Fc1ccc(-c2ccc3nc(NCCc4ccccn4)ncc3c2)c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.51
CDK9 P50750 1/20 0.44
NAMPT P43490 2/20 0.43
FGFR1 P11362 1/20 0.42
HTR2C P28335 1/20 0.41
HTR7 P34969 1/20 0.41
GRM5 P41594 1/20 0.39
RPS6KB1 P23443 3/20 0.39
CYP1A2 P05177 1/20 0.39
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CTNNB1 P35222 1/20 0.37
TCF7L2 Q9NQB0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5496788 0.92 MAPK8 (0.49) MAPK8CDK9NAMPTFGFR1HTR2C
SCHEMBL5488816 0.91 KDM4E (0.46) MAPK8CDK9NAMPTFGFR1HTR2C
SCHEMBL5498308 0.90 MAPK8 (0.47) MAPK8CDK9NAMPTFGFR1HTR2C
SCHEMBL5492004 0.88 NAMPT (0.48) MAPK8CDK9NAMPTFGFR1HTR2C
SCHEMBL5489127 0.86 FGFR1 (0.44) MAPK8CDK9NAMPTFGFR1HTR2C
SCHEMBL5497134 0.85 MAPK8 (0.45) MAPK8CDK9NAMPTFGFR1HTR2C
SCHEMBL5490633 0.82 GBA1 (0.47) MAPK8FGFR1RPS6KB1CYP1A2ALDH1A1
SCHEMBL5490452 0.82 LCK (0.52) MAPK8FGFR1CYP1A2OGAACP1
SCHEMBL5494839 0.82 FGFR1 (0.52) MAPK8CDK9FGFR1CYP1A2KDM4E
SCHEMBL5498074 0.82 BACE1 (0.46) MAPK8FGFR1CYP1A2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 MAPK8 200/4885CDK9 158/4885NAMPT 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.